Former Intermune CEO W. Scott Harkonen is asking the Supreme Court to review his conviction for wire fraud in a case involving off-label marketing of Actimmune. Harkonen issued a press release stating that a clinical trial confirmed Actimmune's efficacy against idiopathic pulmonary fibrosis, though the drug was not FDA-approved for that indication. Harkonen asserts that the conviction violates his right to free speech and that the statements he made were not false or misleading.

Full Story:

Related Summaries